ImmaticsIMTX
IMTX
About: Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Employees: 423
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
130% more call options, than puts
Call options by funds: $1.66M | Put options by funds: $722K
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0.77% less ownership
Funds ownership: 77.31% [Q4 2024] → 76.54% (-0.77%) [Q1 2025]
11% less funds holding
Funds holding: 85 [Q4 2024] → 76 (-9) [Q1 2025]
37% less capital invested
Capital invested by funds: $656M [Q4 2024] → $412M (-$244M) [Q1 2025]
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
63%
upside
Avg. target
$10
63%
upside
High target
$10
63%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Deutsche Bank James Shin | 63%upside $10 | Buy Initiated | 28 May 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
1 week ago
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
The mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
2 weeks ago
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Stafford , Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma. The longer follow-up of patients demonstrates a consistent and favorable tolerability profile as well as durable responses with a confirmed ORR of 56%. In addition, the Company provided details from a Trial in Progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor.
Neutral
GlobeNewsWire
1 month ago
Immatics Announces First Quarter 2025 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, May 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2025.
Neutral
GlobeNewsWire
1 month ago
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago, Illinois.
Negative
Seeking Alpha
2 months ago
Immatics N.V.: Trading Below Cash, But Not Without Reason
Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but negative enterprise value due to early-stage data and long catalyst desert. Phase 3 trial for IMA203 will produce interim data in early 2026, with no clear topline data timeline, creating uncertainty.
Neutral
GlobeNewsWire
2 months ago
Immatics Announces Full Year 2024 Financial Results and Business Update
Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter and full year ended December 31, 2024.
Positive
Zacks Investment Research
4 months ago
New Strong Buy Stocks for February 12th
BOH, AUB, BHRB, IMTX and RH have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2025.
Positive
Zacks Investment Research
5 months ago
New Strong Buy Stocks for January 9th
AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
Positive
Zacks Investment Research
5 months ago
Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock?
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
6 months ago
What Makes Immatics (IMTX) a New Buy Stock
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Charts implemented using Lightweight Charts™